Sterling Capital Management
CSTL icon

Sterling Capital Management’s Castle Biosciences CSTL Stock Holding History

Sterling Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$20.7K Sell
583
-20
-3% -$604 ﹤0.01% 2178
2026
Q2 		$14.4K Sell
603
-368
-38% -$8.2K ﹤0.01% 2042
2026
Q1 		$23.8K Sell
971
-666
-41% -$21.8K ﹤0.01% 1955
2025
Q4 		$63.7K Sell
1,637
-323
-16% -$10.4K ﹤0.01% 1711
2025
Q3 		$44.6K Buy
1,960
+1,193
+156% +$24.2K ﹤0.01% 1790
2025
Q2 		$15.7K Buy
767
+451
+143% +$8.35K ﹤0.01% 1885
2025
Q1 		$6.33K Sell
316
-256
-45% -$6.34K ﹤0.01% 2040
2024
Q4 		$15.2K Buy
572
+500
+694% +$15.2K ﹤0.01% 1970
2024
Q3 		$2.05K Buy
+72
New +$1.83K ﹤0.01% 2173

Other funds holding CSTL

Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

Sterling Capital Management's CSTL Position: Q3 2026 in Review

Sterling Capital Management reduced its Castle Biosciences (CSTL) stake by 3.3% in Q3 2026, selling an estimated $604 and leaving 583 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2178.

Sterling Capital Management first reported a position in CSTL in Q3 2024 and has held it in 9 quarters since. The position peaked at $63.7K in Q4 2025. 97 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Sterling Capital Management held 583 shares of Castle Biosciences worth $20.7K as of Q3 2026.
  • Sterling Capital Management sold 20 Castle Biosciences shares in Q3 2026, an estimated $604.
  • Castle Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2178 holding.
  • Sterling Capital Management first reported a position in Castle Biosciences in Q3 2024 and has held it in 9 quarters since.
  • Sterling Capital Management's Castle Biosciences position peaked at $63.7K in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.